Quantcast
Last updated on April 21, 2014 at 12:45 EDT

Latest XEOMIN Stories

2013-01-20 23:00:42

On January 9, 2013 the 10-month court injunction on Botox competitor Xeomin expired. Simon Ourian, M.D. of Epione Beverly Hills says that competition is good for the industry and consumers alike. Los Angeles, CA (PRWEB) January 20, 2013 “I don´t see how this can be anything but a good thing for consumers,” opines Dr. Ourian, Medical Director of Epione Beverly Hills. “First there was Botox, then Dysport and now Xeomin, each with certain distinct attributes. This can...

2011-12-30 16:00:00

MDLSV now offering Xeomin for the temporary improvement in the appearance of moderate to severe glabellar lines (frown lines), months before the full national release, due to the elite status and extensive experience of MDLSV´s physicians. Baltimore, MD (PRWEB) December 30, 2011 MDLSV now offering Xeomin for the temporary improvement in the appearance of moderate to severe glabellar lines (frown lines), months before the full national release, due to the elite status and extensive...

2011-10-25 07:11:00

GREENSBORO, N.C., Oct. 25, 2011 /PRNewswire/ -- Merz Pharmaceuticals, LLC, today announced that data from studies evaluating the dosing and adverse event profiles of Xeomin® (incobotulinumtoxinA), a botulinum toxin type A free from accessory proteins, in the treatment of blepharospasm (eyelid spasms) will be presented at the 115th Annual Meeting of the American Association of Ophthalmology (AAO) in Orlando, Fla. These data include an extension of the Phase III,...

2011-04-14 07:11:00

GREENSBORO, N.C., April 14, 2011 /PRNewswire/ -- Merz Pharmaceuticals, LLC, maker of XEOMIN® (incobotulinumtoxinA), a botulinum toxin type A free from accessory proteins, today announced the launch of the "Make Your Mark" campaign. With the help of patient advocates, "Make Your Mark" celebrates the inspirational stories of people living with blepharospasm or cervical dystonia (CD), also known as spasmodic torticollis, and aims to raise awareness of these often...

2011-03-30 07:11:00

GREENSBORO, N.C., March 30, 2011 /PRNewswire/ -- Merz Pharmaceuticals, LLC announced today that the Centers for Medicare and Medicaid Services (CMS) has granted a unique Healthcare Common Procedure Coding System (HCPCS) billing code, Q2040, for Xeomin® (incobotulinumtoxinA). Merz expects that this unique billing code, which will become effective on April 1, 2011, will help simplify the billing and reimbursement process for prescribers of XEOMIN. The U.S. Food and Drug...

2010-04-13 07:11:00

GREENSBORO, N.C., April 13 /PRNewswire/ -- Merz Pharmaceuticals announces that results from several new studies examining Xeomin® (incobotulinumtoxinA), a botulinum neurotoxin type A (free from complexing proteins), also referred to as NT 201, will be presented today at the 62nd American Academy of Neurology (AAN) annual meeting in Toronto, Canada. Results of studies exploring the safety and efficacy of Xeomin® in the treatment of focal dystonias...